Preetam Shah - Mar 31, 2022 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
CFO & CBO
Signature
/s/ Preetam Shah
Stock symbol
CDTX
Transactions as of
Mar 31, 2022
Transactions value $
-$20,601
Form type
4
Date filed
4/4/2022, 05:21 PM
Previous filing
Nov 15, 2021
Next filing
Sep 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDTX Common Stock Award $0 +51.3K +256.25% $0.00 71.3K Mar 31, 2022 Direct F1
transaction CDTX Common Stock Award $0 +66K +92.63% $0.00 137K Mar 31, 2022 Direct F2
transaction CDTX Common Stock Tax liability -$20.6K -24.8K -18.08% $0.83 112K Mar 31, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Employee Stock Option (right to buy) Award $0 +103K $0.00 103K Mar 31, 2022 Common Stock 103K $0.83 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents time-based Restricted Stock Units (RSUs) granted on March 31, 2022. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2023, 2024, and 2025, subject to continuous service through each such vesting date.
F2 Represents RSUs granted on March 31, 2022. All RSUs are fully vested as of the grant date.
F3 Shares withheld for taxes on RSU vesting.
F4 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022.